STOCK TITAN

Celularity (NASDAQ: CELU) CEO gains shares from RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Celularity Inc Chief Executive Officer Robert J. Hariri reported routine equity compensation activity involving restricted stock units (RSUs). On April 13, 2026, 3,281 RSUs granted on April 13, 2022 vested and converted into 3,281 shares of Class A Common Stock, representing 25% of a 13,123-RSU award.

To cover tax obligations on this vesting, 1,182 shares of Class A Common Stock were withheld at $1.28 per share, a non–open-market disposition. Following these transactions, Hariri directly holds 2,853,553 shares of Celularity Class A Common Stock.

Positive

  • None.

Negative

  • None.
Insider Hariri Robert J
Role Chief Executive Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 3,281 $0.00 --
Exercise Class A Common Stock 3,281 $0.00 --
Tax Withholding Class A Common Stock 1,182 $1.28 $2K
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Class A Common Stock — 2,854,735 shares (Direct)
Footnotes (1)
  1. Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026. Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.
RSUs vested 3,281 units Portion of 13,123-RSU grant vested on April 13, 2026
Original RSU grant 13,123 units RSUs granted on April 13, 2022
Vesting percentage 25% Portion of April 13, 2022 RSU grant that vested on April 13, 2026
Shares withheld for taxes 1,182 shares Class A Common Stock withheld on RSU vesting
Tax withholding price $1.28 per share Valuation used for 1,182 withheld shares
Shares after transactions 2,853,553 shares CEO’s direct Class A holdings following RSU vesting and tax withholding
Restricted Stock Units financial
"Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding financial
"This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026."
Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.
economic equivalent financial
"Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock."
Form 4 regulatory
"The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hariri Robert J

(Last)(First)(Middle)
C/O CELULARITY INC.
170 PARK AVENUE

(Street)
FLORHAM PARK NEW JERSEY 07932

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Celularity Inc [ CELU ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock04/13/2026M(1)3,281(1)A$02,854,735D
Class A Common Stock04/13/2026F(2)1,182D$1.282,853,553D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(3)04/13/2026M3,281 (4) (4)Class A Common Stock3,281$00D
Explanation of Responses:
1. Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.
2. This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026.
3. Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.
4. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.
/s/ Robert J. Hariri04/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Celularity (CELU) report for its CEO?

Celularity reported that CEO Robert J. Hariri had 3,281 restricted stock units vest and convert into 3,281 Class A shares. These RSUs are part of a prior equity grant and represent routine compensation rather than an open-market stock purchase or sale.

How many Celularity (CELU) RSUs vested for the CEO and from which grant?

3,281 RSUs vested for CEO Robert J. Hariri from a 13,123-RSU grant awarded on April 13, 2022. The filing states this vesting equals 25% of that original grant, with the vested RSUs converting on April 13, 2026 into an equal number of Class A shares.

Were any Celularity (CELU) shares sold by the CEO in this Form 4 filing?

The CEO did not execute an open-market sale. Instead, 1,182 shares of Class A Common Stock were withheld to satisfy tax obligations related to the RSU vesting. This tax-withholding disposition is described as payment of tax liability by delivering securities, not a discretionary stock sale.

What price was used for the tax withholding on Celularity (CELU) shares?

The filing shows 1,182 Celularity Class A shares withheld for taxes at a price of $1.28 per share. This figure is used to value the tax-withholding disposition associated with the vested restricted stock units and does not represent an open-market trade price set by the CEO.

How many Celularity (CELU) shares does the CEO hold after these transactions?

After the RSU vesting and related tax withholding, CEO Robert J. Hariri directly owns 2,853,553 shares of Celularity Class A Common Stock. This post-transaction holding reflects the net position following conversion of 3,281 RSUs and withholding of 1,182 shares for tax obligations.

What is the relationship between Celularity (CELU) RSUs and Class A Common Stock?

Each Celularity restricted stock unit is described as the economic equivalent of one share of Class A Common Stock. Upon vesting, RSUs convert into the same number of Class A shares, as shown when 3,281 RSUs vested and converted into 3,281 Class A Common Stock shares.